SCHEMBL16815249

SCHEMBL16815249

COc1c(F)cccc1C=CC(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 2/20 0.54
KDM4E B2RXH2 2/20 0.52
GAA P10253 1/20 0.49
MCL1 Q07820 1/20 0.48
TRPM8 Q7Z2W7 1/20 0.48
MAOB P27338 1/20 0.48
KRAS P01116 2/20 0.47
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
NFKB1 P19838 1/20 0.46
CA4 P22748 1/20 0.46
RELA Q04206 1/20 0.45
ALDH1A1 P00352 1/20 0.45
HTR1A P08908 1/20 0.45
HPGD P15428 1/20 0.45
HTR2C P28335 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MIF P14174 1/20 0.45
CYP1A1 P04798 1/20 0.45
CYP1A2 P05177 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16815247 1.00 NFE2L2 (0.54) NFE2L2KDM4EGAAMCL1TRPM8
SCHEMBL30739527 1.00 NFE2L2 (0.54) NFE2L2KDM4EGAAMCL1TRPM8
SCHEMBL29090911 0.87 KDM4E (0.57) NFE2L2KDM4EGAAMCL1TRPM8
SCHEMBL29728703 0.87 KDM4E (0.57) NFE2L2KDM4EGAAMCL1TRPM8
SCHEMBL26877070 0.85 MAOB (0.64) MCL1MAOBKRASNFKB1RELA
SCHEMBL16815432 0.82 NFE2L2 (0.55) NFE2L2KDM4EGAATRPM8CA1
SCHEMBL16815431 0.82 NFE2L2 (0.55) NFE2L2KDM4EGAATRPM8CA1
SCHEMBL1056670 0.82 NFE2L2 (0.79) NFE2L2KDM4EGAATRPM8MAOB
SCHEMBL6776487 0.82 NFE2L2 (0.79) NFE2L2KDM4EGAATRPM8MAOB
SCHEMBL10445525 0.82 CA1 (0.62) NFE2L2KDM4EGAATRPM8MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117380269-B Oil-soluble organic molybdenum catalyst and preparation method and application thereof 北京高新利华科技股份有限公司 2024-04-05 CN claimed
CN-117380269-A Oil-soluble organic molybdenum catalyst and preparation method and application thereof 北京高新利华科技股份有限公司 2024-01-12 CN claimed
CN-117380269-B Oil-soluble organic molybdenum catalyst and preparation method and application thereof 北京高新利华科技股份有限公司 2024-04-05 CN disclosed
CN-117380269-A Oil-soluble organic molybdenum catalyst and preparation method and application thereof 北京高新利华科技股份有限公司 2024-01-12 CN disclosed
US-20190201404-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SERVIER LAB (FR) 2019-07-04 US disclosed
US-10278972-B2 Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2019-05-07 US disclosed
US-20170216293-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2017-08-03 US disclosed
US-9670227-B2 Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2017-06-06 US disclosed
EP-2886545-B1 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2016-06-29 EP disclosed
WO-2015097123-A1 NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2015-07-02 WO disclosed
US-20150175623-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2015-06-25 US disclosed
EP-2886545-A1 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2015-06-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170216293-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM TYMS, TYMP, TPX2 NFE2L2 646/4885KDM4E 3097/4885GAA 3943/4885
US-10278972-B2 Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them TYMS, TYMP, TPX2 NFE2L2 646/4885KDM4E 3097/4885GAA 3943/4885
US-20190201404-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM TYMS, TYMP, TPX2 NFE2L2 646/4885KDM4E 3097/4885GAA 3943/4885
US-20150175623-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM TYMS, TYMP, TPX2 NFE2L2 646/4885KDM4E 3097/4885GAA 3943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.